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Background: The selection of patients who will undergo sentinel lymph node biopsy is primarily
based on the histopathologic features of cutaneous melanoma. The purpose of this study is to
identify prognostic factors that predict the sentinel lymph node metastasis in melanoma.
Methods: Sixty-nine melanoma patients underwent sentinel lymph node biopsy at Padova
Plastic Surgery Institute. Univariate chi-square and multivariate logistic regression analy-
ses were conducted to identify the relationship between prognostic factors and positive
sentinel lymph node. A Receiver Operating Characteristics (ROC) Curve was performed to
identify the ideal Breslow thickness cutpoint at which to perform sentinel node biopsy.
Results: Eleven of the 69 patients (16%) had sentinel lymph node metastases. By univariate
analyses Breslow’s thickness ( p¼ 0.001) , ulceration ( p¼ 0.001), and lymphovascular inva-
sion ( p< 0.0001) were found to be significant prognostic factors for the prediction of
sentinel node micrometastases. The ROC Curve identified a Breslow thickness of
1.19 mm to be the most suitable cutpoint for sentinel lymph node positivity ( p¼ 0.003,
sensibility 80%, specificity 69.6%).
Conclusions: Patients with Breslow thickness 1.19 mm, ulceration, and lymphovascular
invasion are at higher risk for occult lymph node metastases. In addition it is important
to use multiple selection criteria when performing sentinel lymph node biopsy especially
in patients with thin melanomas.
ª 2008 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction One of the most controversial arguments of the surgicalThe identification of the prognostic factors of cutaneous mel-
anoma, which are closely related to the metastatic progres-
sion of the tumor itself, provides an important argument for
the management of melanoma patients. Historically the fac-
tors that mainly influence the overall survival are represented
by an increasing Breslow thickness and Clark level, ulceration,
increasing mitotic rate, advanced age and male gender.1,2/306948278810; fax: þ39
Papanikolaou).
al Associates Ltd. Publishapproach to the cutaneous melanoma was represented in
the past by the therapeutic value of the elective lymph node
dissection (ELND) in patients with clinically negative lymph
nodes. Numerous retrospective studies have suggested that
patients who have undergone ELND presented survival benefit
when compared to those who had only observation.3–5 More
recent prospective randomized trials have failed to demon-
strate a survival benefit debating the utility of prophylactic0498213687/302651099768.
ed by Elsevier Ltd. All rights reserved.
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early 1990s when sentinel lymph node biopsy (SLNB) was
introduced for the management of cutaneous melanoma
patients without clinical evidence of regional lymph node me-
tastases.8,9 SLNB is proposed as an alternative technique to
ELND, which is minimally invasive, with less morbidity, and
is able to identify patients at high risk who may benefit from
additional therapies such as complete lymphadenectomy or
adjuvant interferon.
The histological status of sentinel lymph node (SLN) is now
proved to accurately reflect the true histological status of the
entire nodal basin.10,11 Based on this prospective, it is impor-
tant to identify and select the patients who will undergo
SLNB. The indications to perform this procedure, which are
still under discussion, are based mainly on the clinicopatho-
logical features of the primary tumor.
The purpose of this study is to identify those prognostic
factors of cutaneous melanoma that predict SLN metastases
and consider them as selection criteria for SLNB.
1.1. Patients and methods
A total of 69 cutaneous melanoma patients were treated at the
Institute of Plastic Surgery of University Hospital of Padova,
Italy from January 1 1999 to December 31 2002 and were en-
rolled in this retrospective study. All patients who underwent
SLNB met the following selection criteria: (1) histological diag-
nosis of cutaneous melanoma, (2) melanoma origin from any
cutaneous site, (3) Breslow thickness 1.00 mm and/or IV/V
Clark level or presence of ulceration or spontaneous regression,
independently of Breslow thickness or Clark level, (4) clinical
stage I or II, (5) age from 16 to 75 years, (6) patients consent,
and (7)date of theprimary tumorexcision should not supercede
90 days from SLNB. The exclusion criteria were: (1) presence of
lymph node metastases or distant metastases, (2) pregnancy,
(3) ocular or mucosal primary tumor, (4) reconstruction of the
wide local excision with rotation flap, (5) margins of primary
tumor excision more than 2.00 cm, and (6) SLN at the parotid
area (evident by preoperative lymphoscintigraphy).
1.2. Sentinel lymph node biopsy technique
Preoperative lymphoscintigraphy was performed 24 h before
the operation with perilesional intradermal injection (within
1.00 cm from the scar) using 0.5–1.0 ml of 99mTc labelled with
nanocolloidal albumin, which corresponds to 30–70 MBq of
radioactive material. After the injection of colloid, a continu-
ous whole body monitoring was performed until SLN was
clearly identified as the first ‘‘hot’’ lymph node. Afterwards,
multiple acquisitions of images were repeated in specific
time: after 0–5 min, 30 min and 2–3 h after the injection. The
computerized elaboration of the obtained images has allowed
the identification and marking on the skin of the projection of
SLN. The injection site and the lymph node basin are visual-
ized in the same image. In the later acquired images (after at
least 2 h), after the ‘‘washing’’ of the lymphatic vessels, it
was possible to show ‘‘in transit’’ nodes situated between
primary tumor site and the regional lymph node basin. In
this case, the visualized lymph nodes are considered sentinel
lymph nodes (SLNs). After that and during intraoperativeresearch of SLN, a hand-held gamma probe (ScintiProbe
MR100 POL.HI.TECH) was used for exploring the nodal basins,
which was identified by the preoperative lymphoscintigraphy.
The SLNs were identified by researching the peaks of radioac-
tivity with the appropriate gamma probe.
Harvested SLNs underwent histological analysis. Since the
SLNs contained radioactive material, they were fixed in for-
malin and conserved for 12–24 h in a separate container. After
the fixation the dimensions and the consistence of the SLNs
were noticed: the description included the diameters, the
state of the capsule, the consistence, the color and the aspect
of the cut’s surface and the surrounding tissue. The SLNs were
dissected along the major axis and were included separately
in paraffin. When the SLNs were more than 1 cm in diameter,
parallel sections of 2 mm thickness were performed. Conven-
tional histological staining with hematoxylin and eosin (H&E)
and immunohistochemical staining for S-100 protein and
melanoma-associated antigen HMG-45 was performed.
Patients with positive SLNs underwent a complete lymph
node dissection of the affected basins. The mean follow-up
time was 23 months (range, 3–43 months).
1.3. Statistical analysis
The clinical charts and the histological reports of these 69 pa-
tients were examined. The clinico-histopathological features
of the cutaneous melanoma that was studied were: patients’
age, gender, primary tumor site, histological subtype of the
melanoma, Breslow thickness, Clark level, ulceration, regres-
sion, mitotic index, lymphocytic tumor infiltrate, lymphovas-
cular invasion and vertical growth phase.
Statistical analysis was performed using an SPSS (Statisti-
cal Package for the Social Sciences) statistical software (SPSS
v. 10.0.5, SPSS Inc., Chicago, IL., USA). The chi-square test
was used for univariate analysis of categorical data. The
Mann–Whitney test was used to assess the distribution of
continuous variables in different subgroups. Receiver Operat-
ing Characteristics (ROC) Curve was used for identification of
the best cutpoint of Breslow thickness in predicting a positive
SLN. Logistic regression with the help of backward selection
was used for multivariate analysis. Only the preoperative
variables whose p< 0.05 at univariate analysis were included
in the regression model. A p< 0.05 was considered statistically
significant.2. Results
In a total of 69 patients, 37 were male (54%) and 32 were female
(46%). The mean Breslow thickness was 1.32 mm (range,
0.19–8.75 mm) and 18.8% of the patients presented ulceration,
demonstrating a significant increase of ulceration incidence
with the progressive increase of Breslow thickness ( p< 0.05).
At least 1 lymph node basin containing SLN was identified
in all patients (100%). In a total of 76 mapped nodal basins, 8
were cervical (10.5%), 43 axillary (56.5%), 21 inguinal
(28%), while in 4 patients (5%) the SLN was present in other
lymph node basins (2 supraclavicular, 1 lateral thoracic and
1 into the internal mammary chain). In 63 patients (91.3%)
a unique lymph node drainage basin was identified during
Table 1 – Distribution of prognostic factors by sentinel
lymph node biopsy
Prognostic factor SLN () SLN (þ)
No. of
patients (%)
No. of
patients (%)
Total 58 (84) 11 (16)
Sex
Male 29 (78) 8 (22)
Female 29 (90) 3 (10)
Age (years)
54 30 (88) 4 (12)
>54 28 (80) 7 (20)
Site of primary tumor
Head/neck 6 (100) 0 (0)
Trunk 26 (76) 8 (24)
Upper limb 9 (100) 0 (0)
Lower limb 17 (85) 3 (15)
Tumor subtype
Superficial spreading 43 (93) 3 (7)
Nodular 4 (44) 5 (56)
Lentigo maligna 1 (100) 0 (0)
Acral lentiginous 0 (0) 0 (0)
All others 6 (86) 1 (14)
Indeterminate 4 (67) 2 (33)
Breslow thickness (mm)
Median 0.8 2.4
Mean 1.02 2.85
T1: 1 36 (97) 1 (3)
T2: 1.01–2.00 14 (78) 4 (22)
T3: 2.01–4.00 6 (60) 4 (40)
T4: >4.00 0 (0) 1 (100)
Data not available 2 (67) 1 (33)
Clark level
II 12 (92) 1 (8)
III 23 (85) 4 (85)
IV 22 (85) 4 (15)
V 0 (0) 1 (100)
Data not available 1 (50) 1 (50)
Ulceration
Present 7 (54) 6 (46)
Absent 50 (91) 5 (9)
Data not available 1 (100) 0 (0)
Regression
Present 27 (96) 1 (4)
Absent 30 (75) 10 (25)
Data not available 1 (100) 0 (0)
Mitotic index
High (6 mitoses/hpf) 8 (62) 5 (38)
Intermediate (3–5 mitoses/hpf) 5 (100) 0 (0)
Low (2 mitoses/hpf) 7 (70) 3 (30)
Data not available 8 (73) 3 (27)
Lymphocytic tumor infiltrate
Brisk 13 (100) 0 (0)
Moderate 17 (81) 4 (9)
Minimal/absent 21 (78) 6 (22)
Data not available 7 (87.5) 1 (12.5)
hpf, high-power field; SLN, sentinel lymph node.
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phatic basins and only in 1 patient (1.5%) 3 synchronous lym-
phatic basins were identified.
During surgery, at least one SLN was identified by using the
hand-held gamma probe in all patients (100%). After that a to-
tal of 90 SLN (mean, 1.18 sentinel node per basin; range, 1–5
sentinel nodes) were removed.
SLN metastases were diagnosed in 11 of the 69 patients
(16%). These 11 patients underwent a complete lymph node
dissection, which has demonstrated the presence of addi-
tional lymph node metastases in 3 patients (27.3%). The distri-
bution of the prognostic factors based on the results of the SLN
histological status is illustrated in Table 1.
The univariate analysis, performed by chi-square test, was
realized to demonstrate possible relations between cutaneous
melanoma prognostic factors and the identification of SLN
metastases (Table 2). The prognostic factors that resulted to
be statistically significant for the identification of SLN metas-
tases were lymphovascular invasion ( p< 0.0001), Breslow
thickness as a T category variable ( p¼ 0.001) and ulceration
( p¼ 0.001).
ROC Curve was applied so as to obtain the optimal Breslow
thickness cutpoint in relation to positive SLN (Fig. 1). In this
way, it was demonstrated that Breslow thickness of 1.19 mm
is an accurate cutpoint for the presence of SLN metastases.
This cutpoint of 1.19 mm ( p¼ 0.003) has presented a sensitivity
of80% and a specificityof69.6%, whileROC Curve ( p¼ 0.009)has
presented an area under the curve of 0.762 and a standard error
of 0.096. Moreover, only 4.9% of the patients with Breslow thick-
ness <1.19 mm presented with positive SLN, while 32% of the
patients with Breslow thickness>1.19 mm had positive SLN.
Multivariate logistic regression analysis has proved the
non-significance of the prognostic factors included in the
model, data attributed to the fact that the analysis was
restricted at a small number of patients (only 55 patients
with complete clinical data).
During a mean follow-up of 23 months (range, 3–43 months)
on 31 patients without lymph node metastases, for whom it
was possible to have complete clinical data, 30 patients
did not present recurrence and only one patient presented
local recurrence. Therefore, in eight patients with lymph
node metastases (who had complete clinical data) five are
disease free, while three patients are deceased, one due toTable 2 – Univariate chi-square analysis of prognostic
factors associated with sentinel lymph node (SLN)
micrometastasis
Prognostic factor p-Value
Sex 0.166
Site of primary tumor 0.229
Tumor subtype 0.002
Breslow thickness (mm) 0.001
Clark level 0.1
Ulceration 0.001
Regression 0.011
Mitotic index 0.012
Lymphocytic tumor infiltrate 0.178
Lymphovascular invasion <0.0001
Vertical growth phase 0.108
Fig. 1 – Receiver Operating Characteristics (ROC) Curve
demonstrates that the most significant cutpoint is at
1.19 mm.
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tients due to metastatic diffusion of the primary tumor.3. Discussion
SLNB is confirmed to be a valid and accurate technique for the
precise staging of cutaneous melanoma patients.12,13 The
principal objective of this procedure, minimally invasive, is
to identify lymph node micrometastases (clinically occult
metastases) when the tumor is still in an early stage.
The histological results of SLN with a positivity rate of 16%
in this study are similar to other studies (12–36%)12,14–16 and
show that the prophylactic lymph node dissection which
a large number of melanoma patients had undergone, before
the introduction of SLNB technique, was substantially super-
fluous. The significant relation between the Breslow thickness
increase and the increase of lymphatic metastases percent-
ages indicates the primary importance of Breslow thickness
as a cutaneous melanoma prognostic factor. In forty-six per-
cent (46%) of patients the ulceration presence was noticeably
superior to 9% in cases of ulceration absence in relation to
SLN metastases. Balch et al.1 have demonstrated that ulcera-
tion incidence increases with Breslow thickness increment
and ranges between 6% for thin lesions (1.00 mm) and 63%
for thick lesions (>4.00 mm).
This study based on univariate analyses, has showed that
the most significant factors for the prediction of SLN positivity
which have to be taken into consideration for the selection of
patients to undergo SLNB, are lymphovascular invasion, Bre-
slow thickness and ulceration. Various authors suggest the
same prognostic factors for identifying patients at high risk
of lymph node metastases.2,17–19 Zettersten et al.20 havedemonstrated that in patients with thick cutaneous
melanoma (>4.00 mm) tumor thickness, ulceration, mitotic
rate, microsatellites, vascular involvement, and histogenetic
type of the primary tumor were found to be significant for the
overall survival. Ulceration and lymphovascular invasion are
variables whose significance depends on Breslow thickness.
It has been recently proposed that high mitotic index is of
greater value as a prognostic factor than ulceration.21 The
significance of tumor mitotic rate is shown in thin melanoma
and in younger patients.2,22 We found that mitotic rate was
a less important factor because it was significantly associated
with tumor subtype, Breslow thickness and ulceration. Tumor
mitotic rate must be better studied in large prospective trials
with long-term clinical follow-up. At present mitotic index
does not seem to improve decision in the surgical care of
melanoma patients.
The statistical analysis of ROC Curve has identified the Bre-
slow thickness cutpoint of 1.19 mm ( p¼ 0.003) to be the most
accurate value in the prediction of sentinel node metastases.
With a sensitivity of 80% and a specificity of 69.6%, it can be
used as an initial selection criterion for identifying the
patients at high risk of lymph node metastases who should
undergo SLNB. Similar cutpoints (1.23 and 1.50 mm) are pro-
posed by various studies,17,19,23 although any cutpoint must
be taken into consideration with caution and should be
prudent to use multiple selection factors in patients with
thin cutaneous melanoma.
The ideal criteria for the selection of patients who must
undergo SLNB have not been precisely established yet, in
such a way so as to be universally accepted. Taking into con-
sideration the cost-effectiveness of SLNB in patients with thin
melanomas and the low SLN positivity rate (3%) in patients
with T1 lesions, we selected patients with Breslow thickness
greater of 1.00 mm to perform SLNB. Similarly, in most centers
SLN procedure is mainly offered for patients who present
Breslow thickness more than 0.9–1.00 mm or also in the
presence of major prognostic factors such as ulceration,
regression, high mitotic index and IV–V Clark level indepen-
dently of Breslow thickness.14,17,24,254. Conclusion
The histopathological status of SLN is closely related to the
histological characteristics of cutaneous melanoma. Among
those, the lymphovascular invasion, Breslow thickness
1.19 mm and the presence of ulceration, appear to be the
most significant prognostic factors for the identification of
SLN metastases, and are therefore mainly related to the
disease free interval and the prognosis. Those data acquire
strategic importance for the selection of cutaneous melanoma
affected patients who benefit from SLNB since they are at high
risk of lymph node metastases.Conflict of interest
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